Monopar Therapeutics 8-K

What Happened

• Monopar Therapeutics announced it presented results from a Phase 2 study (NCT04422431) of ALXN1840 (tiomolibdate choline) assessing effects on liver pathology and clinical symptoms in patients with Wilson disease at the European Association for the Study of the Liver (EASL) International Liver Congress 2026. The company filed a Form 8‑K on May 29, 2026 furnishing the presentation as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure).

Key Details

• Study identifier: NCT04422431 (Phase 2).
• Investigational drug: ALXN1840 (tiomolibdate choline).
• Event/date: Presentation at EASL International Liver Congress 2026; 8‑K filed May 29, 2026.
• Disclosure: Presentation furnished as Exhibit 99.1 to the Form 8‑K (Regulation FD).

Why It Matters

• Phase 2 clinical data are a key milestone for ALXN1840’s development in Wilson disease and can influence clinical, regulatory and commercial prospects for the program.
• Filing the presentation on a Form 8‑K makes the data publicly available per Regulation FD, so investors can review the full slide set (Exhibit 99.1) to assess the results and any near‑term implications for the company’s development plans.